The development of accessible screening tools for early cancer detection in dogs represents a significant challenge in veterinary medicine. Routine laboratory data offer a promising, low-cost source for such tools, but their utility is hampered by the non-specificity of individual biomarkers and the severe class imbalance inherent in screening populations. This study assesses the feasibility of cancer risk classification using the Golden Retriever Lifetime Study (GRLS) cohort under real-world constraints, including the grouping of diverse cancer types and the inclusion of post-diagnosis samples. A comprehensive benchmark evaluation was conducted, systematically comparing 126 analytical pipelines that comprised various machine learning models, feature selection methods, and data balancing techniques. Data were partitioned at the patient level to prevent leakage. The optimal model, a Logistic Regression classifier with class weighting and recursive feature elimination, demonstrated moderate ranking ability (AUROC = 0.815; 95% CI: 0.793-0.836) but poor clinical classification performance (F1-score = 0.25, Positive Predictive Value = 0.15). While a high Negative Predictive Value (0.98) was achieved, insufficient recall (0.79) precludes its use as a reliable rule-out test. Interpretability analysis with SHapley Additive exPlanations (SHAP) revealed that predictions were driven by non-specific features like age and markers of inflammation and anemia. It is concluded that while a statistically detectable cancer signal exists in routine lab data, it is too weak and confounded for clinically reliable discrimination from normal aging or other inflammatory conditions. This work establishes a critical performance ceiling for this data modality in isolation and underscores that meaningful progress in computational veterinary oncology will require integration of multi-modal data sources.

Malignant lymphoma subtype classification directly impacts treatment strategies and patient outcomes, necessitating classification models that achieve both high accuracy and sufficient explainability. This study proposes a novel explainable Multi-Instance Learning (MIL) framework that identifies subtype-specific Regions of Interest (ROIs) from Whole Slide Images (WSIs) while integrating cell distribution characteristics and image information. Our framework simultaneously addresses three objectives: (1) indicating appropriate ROIs for each subtype, (2) explaining the frequency and spatial distribution of characteristic cell types, and (3) achieving high-accuracy subtyping by leveraging both image and cell-distribution modalities. The proposed method fuses cell graph and image features extracted from each patch in the WSI using a Mixture-of-Experts (MoE) approach and classifies subtypes within an MIL framework. Experiments on a dataset of 1,233 WSIs demonstrate that our approach achieves state-of-the-art accuracy among ten comparative methods and provides region-level and cell-level explanations that align with a pathologist's perspectives.

We introduce LLM-Lasso, a novel framework that leverages large language models (LLMs) to guide feature selection in Lasso $\ell_1$ regression. Unlike traditional methods that rely solely on numerical data, LLM-Lasso incorporates domain-specific knowledge extracted from natural language, enhanced through a retrieval-augmented generation (RAG) pipeline, to seamlessly integrate data-driven modeling with contextual insights. Specifically, the LLM generates penalty factors for each feature, which are converted into weights for the Lasso penalty using a simple, tunable model. Features identified as more relevant by the LLM receive lower penalties, increasing their likelihood of being retained in the final model, while less relevant features are assigned higher penalties, reducing their influence. Importantly, LLM-Lasso has an internal validation step that determines how much to trust the contextual knowledge in our prediction pipeline. Hence it addresses key challenges in robustness, making it suitable for mitigating potential inaccuracies or hallucinations from the LLM. In various biomedical case studies, LLM-Lasso outperforms standard Lasso and existing feature selection baselines, all while ensuring the LLM operates without prior access to the datasets. To our knowledge, this is the first approach to effectively integrate conventional feature selection techniques directly with LLM-based domain-specific reasoning.

At the beginning of 2024, the American Cancer Society predicted that 2,001,140 new cancer cases and 611,720 cancer deaths would occur in the United States. Now, as the year draws to a close, experts are looking back and reflecting on the discoveries and advances that have been made in the field of cancer treatment and prevention. Fox News Digital spoke with four oncologists from the Sarah Cannon Research Institute in Nashville, Tennessee, about the most notable accomplishments of 2024 and what they see on the horizon for 2025. See the answers and questions below. Krish Patel, M.D., is director of lymphoma research at Sarah Cannon Research Institute in Nashville, Tennessee.

Lymphoma diagnosis, particularly distinguishing between subtypes, is critical for effective treatment but remains challenging due to the subtle morphological differences in histopathological images. This study presents a novel hybrid deep learning framework that combines DenseNet201 for feature extraction with a Dense Neural Network (DNN) for classification, optimized using the Harris Hawks Optimization (HHO) algorithm. The model was trained on a dataset of 15,000 biopsy images, spanning three lymphoma subtypes: Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Mantle Cell Lymphoma (MCL). Our approach achieved a testing accuracy of 99.33\%, demonstrating significant improvements in both accuracy and model interpretability. Comprehensive evaluation using precision, recall, F1-score, and ROC-AUC underscores the model's robustness and potential for clinical adoption. This framework offers a scalable solution for improving diagnostic accuracy and efficiency in oncology.

$\textbf{Purpose}$: Automatic quantification of longitudinal changes in PET scans for lymphoma patients has proven challenging, as residual disease in interim-therapy scans is often subtle and difficult to detect. Our goal was to develop a longitudinally-aware segmentation network (LAS-Net) that can quantify serial PET/CT images for pediatric Hodgkin lymphoma patients. $\textbf{Materials and Methods}$: This retrospective study included baseline (PET1) and interim (PET2) PET/CT images from 297 patients enrolled in two Children's Oncology Group clinical trials (AHOD1331 and AHOD0831). LAS-Net incorporates longitudinal cross-attention, allowing relevant features from PET1 to inform the analysis of PET2. Model performance was evaluated using Dice coefficients for PET1 and detection F1 scores for PET2. Additionally, we extracted and compared quantitative PET metrics, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in PET1, as well as qPET and $\Delta$SUVmax in PET2, against physician measurements. We quantified their agreement using Spearman's $\rho$ correlations and employed bootstrap resampling for statistical analysis. $\textbf{Results}$: LAS-Net detected residual lymphoma in PET2 with an F1 score of 0.606 (precision/recall: 0.615/0.600), outperforming all comparator methods (P<0.01). For baseline segmentation, LAS-Net achieved a mean Dice score of 0.772. In PET quantification, LAS-Net's measurements of qPET, $\Delta$SUVmax, MTV and TLG were strongly correlated with physician measurements, with Spearman's $\rho$ of 0.78, 0.80, 0.93 and 0.96, respectively. The performance remained high, with a slight decrease, in an external testing cohort. $\textbf{Conclusion}$: LAS-Net achieved high performance in quantifying PET metrics across serial scans, highlighting the value of longitudinal awareness in evaluating multi-time-point imaging datasets.

Accurate detection and segmentation of diffuse large B-cell lymphoma (DLBCL) from PET images has important implications for estimation of total metabolic tumor volume, radiomics analysis, surgical intervention and radiotherapy. Manual segmentation of tumors in whole-body PET images is time-consuming, labor-intensive and operator-dependent. In this work, we develop and validate a fast and efficient three-step cascaded deep learning model for automated detection and segmentation of DLBCL tumors from PET images. As compared to a single end-to-end network for segmentation of tumors in whole-body PET images, our three-step model is more effective (improves 3D Dice score from 58.9% to 78.1%) since each of its specialized modules, namely the slice classifier, the tumor detector and the tumor segmentor, can be trained independently to a high degree of skill to carry out a specific task, rather than a single network with suboptimal performance on overall segmentation.

The accurate classification of lymphoma subtypes using hematoxylin and eosin (H&E)-stained tissue is complicated by the wide range of morphological features these cancers can exhibit. We present LymphoML - an interpretable machine learning method that identifies morphologic features that correlate with lymphoma subtypes. Our method applies steps to process H&E-stained tissue microarray cores, segment nuclei and cells, compute features encompassing morphology, texture, and architecture, and train gradient-boosted models to make diagnostic predictions. LymphoML's interpretable models, developed on a limited volume of H&E-stained tissue, achieve non-inferior diagnostic accuracy to pathologists using whole-slide images and outperform black box deep-learning on a dataset of 670 cases from Guatemala spanning 8 lymphoma subtypes. Using SHapley Additive exPlanation (SHAP) analysis, we assess the impact of each feature on model prediction and find that nuclear shape features are most discriminative for DLBCL (F1-score: 78.7%) and classical Hodgkin lymphoma (F1-score: 74.5%). Finally, we provide the first demonstration that a model combining features from H&E-stained tissue with features from a standardized panel of 6 immunostains results in a similar diagnostic accuracy (85.3%) to a 46-stain panel (86.1%).

Patch classification models based on deep learning have been utilized in whole-slide images (WSI) of H&E-stained tissue samples to assist pathologists in grading follicular lymphoma patients. However, these approaches still require pathologists to manually identify centroblast cells and provide refined labels for optimal performance. To address this, we propose PseudoCell, an object detection framework to automate centroblast detection in WSI (source code is available at https://github.com/IoBT-VISTEC/PseudoCell.git). This framework incorporates centroblast labels from pathologists and combines them with pseudo-negative labels obtained from undersampled false-positive predictions using the cell's morphological features. By employing PseudoCell, pathologists' workload can be reduced as it accurately narrows down the areas requiring their attention during examining tissue. Depending on the confidence threshold, PseudoCell can eliminate 58.18-99.35% of non-centroblasts tissue areas on WSI. This study presents a practical centroblast prescreening method that does not require pathologists' refined labels for improvement. Detailed guidance on the practical implementation of PseudoCell is provided in the discussion section.

A new study published by experts in Singapore suggests that an artificial intelligence (AI) platform that identifies patient-specific drug combinations can help those whose lymphomas have relapsed. The paper, published in the journal Science Translational Medicine on October 19, is the first study demonstrating the feasibility of personalized drug combination prediction for patients with lymphoma, and utilizes a novel method called QPOP (quadratic phenotypic optimization platform) that is developed in the National University of Singapore (NUS). The method involves collecting a small tumor sample from a patient and incubating this in a laboratory with a set of 12 carefully selected drugs used for lymphoma. After 72 hours, QPOP then ranks the patient's cancer cells' potential response to more than 750 distinct drug combinations of up to four drugs, using these 12 possible drugs. This clinical application study of QPOP, the first-of-its-kind, was a collaboration between clinicians at the National University Cancer Institute, Singapore (NCIS) and scientists from the Cancer Science Institute of Singapore (CSI Singapore) at NUS.